Following the USPSTF grade "D" recommendation puts patients directly in harm's way. CMS should independently review the scientific data for PSA screening. If they review the data they will find the follow-up period is far too short with far too few events to determine if there is a difference in outcome. They will find a 2011 AHRQ report determined that the studies the USPSTF used were of only "fair quality." They will find that the data were inadequate to determine the benefits in African Americans, Agent Orange exposed Veterans or men with a Family history of Prostate Cancer (Ansbaugh Cancer 2013). They will also find that early detection can lead to the appropriate treatment of prostate cancer which improves survival by 38% (NEJM 2011). CMS should lead instead of follow. Much can be done to educate patients and physicians regarding not only the risks and benefits of treatment but non-treatment as well (ie bone mets, death, urinary obstruction).